Back to top
more

Syndax Pharmaceuticals (SNDX)

(Real Time Quote from BATS)

$20.32 USD

20.32
116,040

-0.44 (-2.12%)

Updated May 23, 2024 11:11 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SNDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Syndax Pharmaceuticals, Inc. [SNDX]

Reports for Purchase

Showing records 21 - 40 ( 46 total )

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

08/09/2022

Company Report

Pages: 8

2Q22 Results; Data From Pivotal Studies of Revumenib and Axatilimab Expected in 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

05/10/2022

Company Report

Pages: 6

1Q22 Results; One or More AUGMENT-101 Pivotal Cohorts to Complete Enrollment in 2022; AGAVE-201 Trial Data Expected 1H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

04/11/2022

Company Report

Pages: 29

Two Potential NDA Filings in 2023; Initiating Coverage With a Buy Rating and $31 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 35.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SNDX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

07/26/2020

Company Report

Pages: 8

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

05/22/2020

Company Report

Pages: 8

E2112 Primary Endpoint Missed; Downgrade to Neutral; Lower PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

05/11/2020

Company Report

Pages: 8

1Q20 Results; Final Countdown to Phase 3 E2112 Data; Raising PT to $25 on SNDX-5613 Expectations

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

04/28/2020

Company Report

Pages: 6

Positive Initial SNDX-5613 Data at AACR; Raising PT to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

04/21/2020

Daily Note

Pages: 3

SNDX-5613 Granted Orphan Drug Designation in AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

03/04/2020

Company Report

Pages: 6

4Q Results; Entinostat OS Data Expected 2Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

02/03/2020

Company Report

Pages: 8

Common Stock Offering and Debt Deal Announced; Reiterating Buy Rating

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

01/13/2020

Company Report

Pages: 8

Management Provides 2020 Corporate Update; Raising PT to $17 from $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

12/10/2019

Daily Note

Pages: 3

Phase 2 Expansion Cohort for SNDX-6352 Announced

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

11/08/2019

Company Report

Pages: 6

3Q19 Results; Entinostat Phase 3 OS Data Expected 2Q20; SNDX-5613 Enters the Clinic

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

10/07/2019

Company Report

Pages: 7

E2112 Trial Passed Final Interim Analysis for OS, Now Looking to 2Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

08/08/2019

Company Report

Pages: 8

2Q19 Results; E2112 OS Analysis Expected in 4Q19

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

07/10/2019

Daily Note

Pages: 3

FDA Clears IND Application for Phase 1/2 Trial of SNDX-5613

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

05/07/2019

Company Report

Pages: 6

1Q19 Results; Fourth Interim Analysis for Overall Survival Completed

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

04/02/2019

Company Report

Pages: 8

Updated Entinostat ENCORE 601 Data at AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Syndax Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

03/08/2019

Company Report

Pages: 8

Reports 4Q18 Results; Prioritizing Portfolio, PT to $16 From $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party